Lysosomal ion channels: TRPML1, TRPML2, TRPML3, TMEM175, and TPC2.

Whether you're a small biotech managing tight budgets or a large pharma striving for efficiency, Metrion is here to help you do more with less.

We mark Rare Disease Day by highlighting a selection of the most detrimental ion channel mutations which can result in a plethora of rare diseases, often involving complex neurological, cardiac, and muscular manifestations.

"The data is always correct and is in a format that imports directly into our systems, making it so quick and easy for our team to review the data across individual projects."

Insight into the history of how automated patch clamp has contributed to enhancing decision making, minimising risk and lowering R&D costs

The inaugural feature, published 19th January, highlights the UK’s fastest-growing private companies developing or selling unique, proprietary technologies, and is backed by Singer Capital Markets, HSBC Innovation Banking and BDO.

The future of drug discovery holds immense promise, and Metrion is well-positioned to make meaningful contributions to advancing human health. I look forward to embarking on this exciting journey with all of you.

As we celebrate this significant milestone, we take pride in the contributions of our entire team, whose expertise and dedication have been instrumental in shaping who we are today. We’re equally grateful to our customers and collaborators, whose trust and partnership have been pivotal to our success.

Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders'

An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.